RNAI AGENTS FOR INHIBITING EXPRESSION OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS, COMPOSITIONS THEREOF, AND METHODS OF USE
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene. Pharmaceutical compositions that...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
14.02.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma. |
---|---|
AbstractList | Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma. |
Author | BUSH, Erik, W KASAHARA, David, Itiro SCHIENEBECK, Casi, M NICHOLAS, Anthony |
Author_xml | – fullname: KASAHARA, David, Itiro – fullname: SCHIENEBECK, Casi, M – fullname: BUSH, Erik, W – fullname: NICHOLAS, Anthony |
BookMark | eNqNzLsOwiAYhmEGHTzdw38B7dDUQxwRfgqJBQLU6NQ0BifTNqm7t64kXoDTN7xPviWZ9UMfF-TtNFVAK9TBgzAOlJbqpILSFeDVOvReGQ1GgEOGNnxFUpRfqGbIoTrfGA2JoOa5dYY3LPgMmKmt8SoVD0GiQyMyoJpDjUEa7tNl43FN5o_uOcXNb1cEBAYm8zgObZzG7h77-GrRbsvieNjvaFH-QT4_Ez1H |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | AGENTS D'INTERFÉRENCE ARN POUR INHIBER L'EXPRESSION D'UN RÉCEPTEUR POUR DES PRODUITS FINAUX DE GLYCATION AVANCÉE, COMPOSITIONS ASSOCIÉES ET MÉTHODES D'UTILISATION RNAI-MITTEL ZUR HEMMUNG DER EXPRESSION VON REZEPTOR FÜR ENDPRODUKTE DER FORTGESCHRITTENEN GLYKIERUNG, ZUSAMMENSETZUNGEN DAVON UND VERFAHREN ZUR VERWENDUNG |
ExternalDocumentID | EP4319765A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_EP4319765A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 12:49:12 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French German |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_EP4319765A13 |
Notes | Application Number: EP20220785435 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240214&DB=EPODOC&CC=EP&NR=4319765A1 |
ParticipantIDs | epo_espacenet_EP4319765A1 |
PublicationCentury | 2000 |
PublicationDate | 20240214 |
PublicationDateYYYYMMDD | 2024-02-14 |
PublicationDate_xml | – month: 02 year: 2024 text: 20240214 day: 14 |
PublicationDecade | 2020 |
PublicationYear | 2024 |
RelatedCompanies | Arrowhead Pharmaceuticals, Inc |
RelatedCompanies_xml | – name: Arrowhead Pharmaceuticals, Inc |
Score | 3.5281641 |
Snippet | Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE)... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
Title | RNAI AGENTS FOR INHIBITING EXPRESSION OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS, COMPOSITIONS THEREOF, AND METHODS OF USE |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240214&DB=EPODOC&locale=&CC=EP&NR=4319765A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3PT8IwFG4IGvWmqBF_pQezE4uwdQsciBltx2akXbZh8ERYmQmXQWTGo_-6rwPRi96a9uUlfcn3vvfavleE7qwZcRTJXVMRkpmkC0if5U7bnCtiATt3lb3p9incYEweJ86khhbftTBVn9CPqjkiIEoB3svKX69-DrFY9bZyfZ8tYGr54Kd9ZmyzY31V0CEGG_R5JJmkBqUwMkTcB54E4nU8SJT2dBSt2-zz54EuSln9ZhT_GO1HoKwoT1AtLxrokH5_vNZAB6PtfTcMt9Bbn6LPWHgh9oZcpAmG1A2HIggHYRqKIeaTypDgFrH0ccwpj1KQ0FJAO_r7GYaHTy-bmmHMBTOjWLIxTZMWpnIUySSsqolxGvCYS7-FPcHwiKeBZIlWOU74GcI-T2lgwk6mO6tNebTbs32O6sWyyC8QdjNlzVy3bdt2j-TK7nXnPcvKXrsQSbVdZTVR8081l_-sXaEjbX79nrlDrlG9fHvPb4Cuy-y2MvQXYqqO8w |
link.rule.ids | 230,309,786,891,25594,76903 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT8IwFG8IGvGmqBE_ezA7sQhbN-FAzFg7NmXtshWDJ8LGTLgMIjMe_dd9Gx960VvTNi95r3nv11_b94rQnTYlRkJSU00IiVXSAU-fpkZLnSVEA3TuJPq62ic33RF5GhvjCppvc2HKOqGfZXFE8KgE_D0v4_Xy5xCLlm8rV_fxHLoWj47sUWXDjourgjZRaL_HAkGFrdg2tBQe9gAnAXgNC4jS3gMwwpIpvfSLpJTlb0RxjtB-AMKy_BhV0qyOavb247U6OvA3993Q3Lje6gR9hdzysDVgXEYYqBv2uOv1PenxAWbj0pAQFrFwcMhsFkiYUcwC2Cm-n6F4MHxd5wxjxqkahIKObBk1sS38QERemU2MpctCJpwmtjjFPpOuoFEhchSxU4QdJm1XBU0mO6tNWLDTWT9D1WyRpecIm3GiTU2zpet6l6SJ3u3MupoWv3VgJ9UyE62BGn-Kufhn7BbVXOkPJ0OPP1-iw2IpirfNbXKFqvn7R3oN0J3HN6XRvwE3X5Hd |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=RNAI+AGENTS+FOR+INHIBITING+EXPRESSION+OF+RECEPTOR+FOR+ADVANCED+GLYCATION+END-PRODUCTS%2C+COMPOSITIONS+THEREOF%2C+AND+METHODS+OF+USE&rft.inventor=KASAHARA%2C+David%2C+Itiro&rft.inventor=SCHIENEBECK%2C+Casi%2C+M&rft.inventor=BUSH%2C+Erik%2C+W&rft.inventor=NICHOLAS%2C+Anthony&rft.date=2024-02-14&rft.externalDBID=A1&rft.externalDocID=EP4319765A1 |